On September 16, 2024, Galmed Pharmaceuticals Ltd. reported that it regained compliance with Nasdaq's minimum bid price requirement after maintaining a closing bid price above $1.00 for 10 consecutive trading days from August 30 to September 13, 2024. This means their shares will continue to be traded on the Nasdaq Stock Market, following a previous notification of non-compliance on September 19, 2023.